We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-43.14%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$100M
AUM Growth
-$36.6M
Cap. Flow
-$10.6M
Cap. Flow %
-10.62%
Top 10 Hldgs %
93.38%
Holding
105
New
21
Increased
12
Reduced
17
Closed
48

Top Buys

Rank Stock Value
1
AIRE icon
reAlpha
AIRE
+$3.43M
2
FMTO
Femto Technologies Inc. Common Stock
FMTO
+$2.56M
3
GGE
Green Giant Inc. Common Stock
GGE
+$2.37M
4
MMAT
Meta Materials Inc. Common Stock
MMAT
+$1.64M
5
PHUN icon
Phunware
PHUN
+$1.41M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$12.9M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$2.67M
3
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$2.17M
4
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$817K
5
AIOS
AIOS Tech
AIOS
+$528K

Sector Composition

Rank Sector Weight
1 Technology 4.2%
2 Healthcare 3.82%
3 Energy 0.81%
4 Real Estate 0.76%
5 Materials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUCYW icon
76
Innovative Eyewear Inc Series A Warrants 8/16/27
LUCYW
$60.6K
– –
-104,535
Closed -$13.5K
NCPL icon
77
Netcapital
NCPL
$2.97M
– –
-4,772
Closed -$137K
AIOS
78
AIOS Tech
AIOS
$41.1M
– –
-11,049
Closed -$528K
NRXP icon
79
NRX Pharmaceuticals
NRXP
$152M
– –
-32,500
Closed -$84.5K
RDHL
80
Redhill Biopharma
RDHL
$4.44M
– –
-25,400
Closed -$324K
RNAZ icon
81
TransCode Therapeutics
RNAZ
$5.29M
– –
-7
Closed -$126K
RVPH
82
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-55
Closed -$536K
RVPH
83
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-2,230
Closed -$218K
RVPH
84
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-56
Closed -$549K
SNGX icon
85
Soligenix
SNGX
$5.36M
– –
-46,285
Closed -$413K
SPY icon
86
State Street SPDR S&P 500 ETF Trust
SPY
$783B
– –
-6,000
Closed -$2.67M
VINC
87
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-2,868
Closed -$57.9K
SEEL
88
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
-3,071
Closed -$2.17M
FRZA
89
DELISTED
Forza X1, Inc. Common Stock
FRZA
– –
-102,787
Closed -$83.8K
BGXX
90
DELISTED
Bright Green Corporation Common Stock
BGXX
– –
-304,183
Closed -$120K
MMAT
91
PUT
DELISTED
Meta Materials Inc. Common Stock
MMAT
– –
-5
Closed -$10K
GMDA
92
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-111,264
Closed -$115K
GMDA
93
PUT
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-2,244
Closed -$231K
VRPX
94
DELISTED
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
– –
-1,171
Closed -$234K
BETS
95
DELISTED
Bit Brother Limited Class A Ordinary Shares
BETS
– –
-567
Closed -$291K
HCDI
96
DELISTED
Harbor Custom Development, Inc. Common Stock
HCDI
– –
-164,516
Closed -$232K
GMVD
97
DELISTED
G Medical Innovations Holdings Ltd. Ordinary Shares
GMVD
– –
-352,922
Closed -$20.4K
MOBQ
98
DELISTED
Mobiquity Technologies, Inc. Common Stock
MOBQ
– –
-144,000
Closed -$96.9K
SMFL
99
DELISTED
Smart for Life, Inc. Common Stock
SMFL
– –
-2,595
Closed -$44.9K
NMTR
100
DELISTED
9 Meters Biopharma
NMTR
– –
-1,672,627
Closed -$20.1K
1 2 3
4
5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sabby Management held 105 positions worth $100M, down 27% from $137M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Sabby Management withdrew a net $10.6M in Q4 2023, closing 48 positions and reducing 17 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $12.9M position sold in full.

By sector, the portfolio is most concentrated in Technology at 4.2% of assets, up from 0.43% a quarter earlier, followed by Healthcare and Energy.

Against the trend, Sabby Management opened a new position in reAlpha worth $370K.

  • Sabby Management's largest Q4 2023 buy was reAlpha: 7,430 shares worth $370K.
  • Sabby Management added most to Tonix Pharmaceuticals in Q4 2023, an estimated $929K increase.
  • Sabby Management's biggest Q4 2023 reduction was GlucoTrack, cutting an estimated $349K.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q4 2023, selling an estimated $12.9M.
  • Sabby Management's ten largest holdings make up 93% of its $100M portfolio in Q4 2023.
  • Sabby Management opened 21 new positions and closed 48 in Q4 2023.
  • Sabby Management's portfolio value fell 27% quarter-over-quarter to $100M.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.